Soden Peter A, Zettervall Sara L, Shean Katie E, Vouyouka Ageliki G, Goodney Philip P, Mills Joseph L, Hallett John W, Schermerhorn Marc L
Division of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass.
Division of Vascular Surgery, Mount Sinai Health Systems, Icahn School of Medicine, New York, NY.
J Vasc Surg. 2017 Sep;66(3):810-818. doi: 10.1016/j.jvs.2017.01.061. Epub 2017 Apr 24.
Increased focus has been placed on perioperative and long-term outcomes in the treatment of peripheral artery disease (PAD), both for purposes of quality improvement and for assessment of performance at a surgeon and institutional level. This study evaluates regional variation in outcomes after treatment for PAD within the Vascular Quality Initiative (VQI). By describing the variation in practice patterns and outcomes across regions, we hope that each regionally based quality group can select which areas are most important for them to focus on as they will have access to their regional data to compare.
We identified all patients in the VQI who had infrainguinal bypass or endovascular intervention from 2009 to 2014. We compared variation in perioperative and 1-year outcomes stratified by symptom status and revascularization type among the 16 regional groups of the VQI. We analyzed variation in perioperative end points using χ analysis, and 1-year end points were analyzed using Kaplan-Meier and life-table analysis.
We identified 15,338 bypass procedures for symptomatic PAD: 27% for claudication, 59% for chronic limb-threatening ischemia (CLI; 61% of these for tissue loss), and 14% for acute limb ischemia. We identified 33,925 endovascular procedures for symptomatic PAD: 42% for claudication, 48% for CLI (73% of these for tissue loss), and 10% for acute limb ischemia. Thirty-day mortality varied significantly after endovascular intervention for CLI (0.5%-3%; P < .001) but not for claudication (0.0%-0.5%, P = .77) or for bypass for claudication (0.0%-2.6%; P = .37) or CLI (0.0%-5.0%; P = .08). After bypass, rates of >2 units transfused red blood cells (claudication, 0.0%-13% [P < .001]; CLI, 6.9%-27% [P < .001]) varied significantly. In-hospital major amputation was variable after bypass for CLI (0.0%-4.3%; P = .004) but not for claudication (0.0%-0.6%; P = .98), as was postoperative myocardial infarction (claudication, 0.0%-4% [P = .36]; CLI, 0.8%-6% [P = .001]). One-year survival varied significantly for endovascular interventions for claudication (92%-100%; P < .001), bypass for CLI (85%-94% [P < .001]), and endovascular interventions for CLI (77%-96%; P < .001) but not after bypass for claudication (95%-100%; P = .57).
In this real-world comparison among VQI regions, we found significant variation in perioperative and 1-year end points for patients with PAD undergoing bypass or endovascular intervention. This study highlights opportunities for quality improvement efforts to reduce variation and to improve outcomes.
外周动脉疾病(PAD)治疗中,围手术期和长期结局受到了更多关注,这既出于质量改进的目的,也用于评估外科医生和机构层面的表现。本研究评估了血管质量改进计划(VQI)中PAD治疗后结局的地区差异。通过描述各地区实践模式和结局的差异,我们希望每个基于地区的质量小组能够选择对他们而言最重要的关注领域,因为他们可以获取本地区的数据进行比较。
我们确定了2009年至2014年VQI中所有接受股动脉以下旁路手术或血管腔内介入治疗的患者。我们比较了VQI的16个地区组中按症状状态和血运重建类型分层的围手术期和1年结局的差异。我们使用χ分析来分析围手术期终点的差异,使用Kaplan-Meier法和生命表分析来分析1年终点。
我们确定了15338例有症状PAD的旁路手术:间歇性跛行占27%,慢性肢体威胁性缺血(CLI;其中61%为组织缺损)占59%,急性肢体缺血占14%。我们确定了33925例有症状PAD的血管腔内介入治疗:间歇性跛行占42%,CLI占48%(其中73%为组织缺损),急性肢体缺血占10%。CLI血管腔内介入治疗后30天死亡率差异显著(0.5%-3%;P<.001),但间歇性跛行(0.0%-0.5%,P=.77)、间歇性跛行旁路手术(0.0%-2.6%;P=.37)或CLI旁路手术(0.0%-5.0%;P=.08)后差异不显著。旁路手术后,输注超过2单位红细胞率(间歇性跛行,0.0%-13%[P<.001];CLI,6.9%-27%[P<.001])差异显著。CLI旁路手术后院内大截肢率存在差异(0.0%-4.3%;P=.004),但间歇性跛行(0.0%-0.6%;P=.98)后无差异,术后心肌梗死(间歇性跛行,0.0%-4%[P=.36];CLI,0.8%-6%[P=.001])也存在差异。间歇性跛行血管腔内介入治疗、CLI旁路手术和CLI血管腔内介入治疗的1年生存率差异显著(92%-100%;P<.001)、(85%-94%[P<.001])和(77%-96%;P<.001),但间歇性跛行旁路手术后无差异(95%-100%;P=.57)。
在VQI各地区的这一真实世界比较中,我们发现接受旁路手术或血管腔内介入治疗的PAD患者围手术期和1年终点存在显著差异。本研究突出了质量改进努力的机会,以减少差异并改善结局。